日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Clinical response to azacitidine in MDS is associated with distinct DNA methylation changes in HSPCs.

MDS 对阿扎胞苷的临床反应与 HSPC 中独特的 DNA 甲基化变化有关

Thoms Julie A I, Yan Feng, Hampton Henry R, Davidson Sarah, Joshi Swapna, Saw Jesslyn, Sarowar Chowdhury H, Lim Xin Ying, Nunez Andrea C, Kakadia Purvi M, Bhuyan Golam Sarower, Zou Xiaoheng, Nguyen Mary, Ghodousi Elaheh S, Koch Forrest C, Vafaee Fatemeh, Thompson I Richard, Karimi Mohammad M, Pickford Russell, Raftery Mark J, Hough Sally, Buckland Griselda, Bailey Michelle, Ghodke Yuvaraj, Absar Noorul, Vaughan Lachlin, Pasalic Leonardo, Fong Chun Y, Kenealy Melita, Hiwase Devendra K, Stoddart Rohanna I, Mohammed Soma, Lee Linda, Passam Freda H, Larsen Stephen R, Spring Kevin J, Skarratt Kristen K, Rebeiro Patricia, Presgrave Peter, Stevenson William S, Ling Silvia, Tiley Campbell, Fuller Stephen J, Roncolato Fernando, Enjeti Anoop K, Hoenemann Dirk, Lemech Charlotte, Jolly Christopher J, Bohlander Stefan K, Curtis David J, Wong Jason W H, Unnikrishnan Ashwin, Hertzberg Mark, Olivier Jake, Polizzotto Mark N, Pimanda John E

Favorable outcomes of DDX41-mutated myelodysplastic syndrome and low blast count acute myeloid leukemia treated with azacitidine ± lenalidomide

采用阿扎胞苷±来那度胺治疗DDX41突变型骨髓增生异常综合征和低原始细胞计数急性髓系白血病可获得良好疗效。

Tiong, Ing S; Stevenson, William S; Wall, Meaghan; Yap, Yan Zhuang; Seymour, John F; Kenealy, Melita; Blombery, Piers

Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia

阿扎胞苷联合或不联合来那度胺治疗高危骨髓增生异常综合征和低原始细胞急性髓系白血病

Kenealy, Melita; Hertzberg, Mark; Benson, Warwick; Taylor, Kerry; Cunningham, Ilona; Stevenson, Will; Hiwase, Devendra; Eek, Richard; Zantomio, Daniela; Jong, Steve; Wall, Meaghan; Blombery, Piers; Gerber, Tracey; Debrincat, Marlyse; Zannino, Diana; Seymour, John F